Gerassimos Lascaratos is a consultant ophthalmic surgeon specialising in glaucoma and cataract surgery at King’s College Hospital in London. He is a Reader (Associate Professor) in Ophthalmology in the School of Life Course and Population Sciences, King’s College London.

Gerassimos has a passion for translational clinical research and is co-leading a novel phase III multicentre randomised clinical trial in glaucoma investigating the role of nicotinamide (NAM) in improving mitochondrial function and delaying disease progression (NAMinG trial). He is also the Principal Investigator at King’s for the TRITON trial, a phase 3b study to evaluate the duration of effect of Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. Gerassimos has been involved as local Principal Investigator in several glaucoma trials and studies, including a large prospective study investigating the role of mitochondrial function as a novel biomarker for glaucoma in collaboration with Moorfields Eye Hospital and the PEACE trial (randomised trial comparing primary trabeculectomy with primary tube surgery in black African and African-Caribbean patients with uncontrolled open angle glaucoma) in collaboration with St Thomas’ Hospital.

His academic work has been funded by the National Institute for Health Research, International Glaucoma Association, Fight for Sight, Moorfields Special Trustees, Allergan Europe and the TFC Frost Charitable Trust. Based on his innovative PhD work at University College London and his MSc work at Oxford University, St Peter’s College, he has unique expertise in cellular bioenergetics in glaucoma and its relevance to the development of new glaucoma treatments. He is a member of the NAM Global Steering Committee and of the UKBB Eye and Vision Consortium.